A comparison between the continual reassessment method and D-optimum design for dose finding in phase I clinical trials

Atkinson A.C., Fedorov V.V., Herzberg A.M., Zhang R. (2014): Elemental information matrices and optimal experimental design for generalized regression models. Journal of Statistical Planning and Inference 144(1): 81–91.10.1016/j.jspi.2012.09.012Search in Google Scholar

Babb J., Rogatko A., Zacks S. (1998): Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17(10): 1103–1120.10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9Search in Google Scholar

Chernoff H. (1953): Locally optimal designs for estimating parameters. The Annals of Mathematical Statistics 24(4): 586–602.10.1214/aoms/1177728915Search in Google Scholar

Collins J.M., Grieshaber C.K., Chabner B.A. (1990): Pharmacologically guided phase I clinical trials based upon preclinical drug development. Journal of the National Cancer Institute 82(16): 1321–1326.10.1093/jnci/82.16.1321Search in Google Scholar

Dixon W.J., Mood A.M. (1948): A method for obtaining and analyzing sensitivity data. Journal of the American Statistical Association 43(241): 109–126.10.1080/01621459.1948.10483254Search in Google Scholar

Goodman S.N., Zahurak M.L., Piantadosi S. (1995): Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14(11): 1149–1161.10.1002/sim.4780141102Search in Google Scholar

Korn E.L., Midthune D., Chen T.T., Rubinstein L.V., Christian M.C., Simon R.M. (1994): A comparison of two phase I trial designs. Statistics in Medicine 13(18): 1799–1806.10.1002/sim.4780131802Search in Google Scholar

Le Tourneau C., Lee J.J., Siu L.L. (2009): Dose escalation methods in phase I cancer clinical trials. Journal of the National Cancer Institute 101(10): 708–720.10.1093/jnci/djp079Search in Google Scholar

Leung D.H.Y., Wang Y.G. (2001): Isotonic designs for phase I trials. Controlled Clinical Trials 22(2): 126–138.10.1016/S0197-2456(00)00132-XSearch in Google Scholar

Lévy V., Zohar S., Porcher R., Chevret S. (2001): Alternate designs for conduct and analysis of phase I cancer trials. Blood 98(4): 1275–1275.10.1182/blood.V98.4.1275Search in Google Scholar

O’Quigley J., Pepe M., Fisher L. (1990): Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46(1): 33–48.10.2307/2531628Search in Google Scholar

O’Quigley J., Shen L.Z. (1996): Continual reassessment method: A likelihood approach. Biometrics 52(2): 673–684.10.2307/2532905Search in Google Scholar

O’Quigley J., Zohar S. (2006): Experimental designs for phase I and phase I/II dose-finding studies. British Journal of Cancer 94(5): 609–613.10.1038/sj.bjc.6602969Search in Google Scholar

Reiner E., Paoletti X., O’Quigley J. (1999): Operating characteristics of the standard phase I clinical trial design. Computational Statistics and Data Analysis 30(3): 303–315.10.1016/S0167-9473(98)00095-4Search in Google Scholar

Simon R., Rubinstein L., Arbuck S.G., Christian M.C., Freidlin B., Collins J. (1997): Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89(15): 1138–1147.10.1093/jnci/89.15.1138Search in Google Scholar

Storer B.E. (1989): Design and analysis of phase I clinical trials. Biometrics 45(3): 925–937.10.2307/2531693Search in Google Scholar